003090 - Daewoong Co., Ltd.

003090 Summary

Biopharma

Stock Price & Overview

₩16,860 -340 (-1.98%) Close · Sep 4, 2026 KST

KOSPI | ₩KRW | Close: ₩16,860 ≈ US$12 · Market cap ₩1.0tn (≈ $700m)

003090 Financial Statements

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Revenue	2.07	1.94	1.81	1.70	1.51	1.36	1.37	1.23	1.12	1.01	1.00
Operating Income	0.26	0.28	0.20	0.21	0.18	0.10	0.11	0.09	0.08	0.06	0.08
Finance Income	0.02	0.02	0.03	0.04	0.03	0.03	0.01	0.01	0.01	0.01	0.01
Finance Costs	0.04	0.05	0.03	0.03	0.02	0.03	0.02	0.02	0.02	—	—
Pretax Income	0.24	0.12	0.20	0.15	0.11	0.14	0.08	0.06	0.08	0.06	0.08
Income Tax Expense	0.02	0.05	0.01	0.03	0.01	0.03	0.01	0.03	-0.00	-0.02	-0.03
Net Income	0.23	0.07	0.19	0.12	0.10	0.12	0.07	0.03	0.09	0.03	0.05
Total Comprehensive Income	0.24	0.07	0.19	0.13	0.05	0.14	0.08	0.04	0.08	0.03	0.05

Breakdown ₩ tn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Total Assets	3.23	2.72	2.36	2.16	1.93	1.83	1.67	1.59	1.55	1.47	1.24
Current Assets	1.03	0.95	0.86	0.95	0.84	0.83	0.76	0.73	0.72	0.70	0.61
Cash & Cash Equivalents	0.26	0.19	0.16	0.19	0.12	0.20	0.07	0.10	0.14	0.11	0.10
Inventories	0.44	0.39	0.35	0.32	0.24	0.25	0.25	0.29	0.25	0.22	0.18
Trade Receivables	0.27	0.27	0.22	0.23	0.19	0.18	0.23	0.20	0.19	0.19	0.16
Non-current Assets	2.20	1.77	1.50	1.20	1.09	1.00	0.91	0.86	0.83	0.77	0.63
Property, Plant & Equipment	1.15	0.96	0.73	0.62	0.60	0.57	0.60	0.61	0.58	0.56	0.44
Intangible Assets	0.38	0.36	0.31	0.28	0.23	0.19	0.17	0.16	0.18	0.16	0.14
Total Liabilities	1.46	1.22	0.92	0.88	0.78	0.72	0.64	0.63	0.61	0.60	0.41
Current Liabilities	0.77	0.72	0.72	0.52	0.51	0.37	0.28	0.38	0.28	0.27	0.18
Non-current Liabilities	0.70	0.50	0.20	0.36	0.26	0.35	0.36	0.25	0.33	0.34	0.24
Total Equity	1.77	1.50	1.44	1.28	1.15	1.11	1.03	0.96	0.94	0.86	0.83
Share Capital	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Retained Earnings	1.11	0.95	0.89	0.75	0.65	0.57	0.49	0.43	0.40	—	—

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015
Cash from Operating Activities	257.6	162.4	205.7	149.1	133.2	145.4	138.5	45.4	147.8	18.8	74.9
Cash from Investing Activities	-367.5	-365.5	-204.8	-105.5	-219.1	-30.8	-150.0	-79.2	-82.5	-181.8	-117.5
Purchase of Property, Plant & Equipment	294.8	262.6	181.4	68.0	68.2	31.6	40.0	65.7	74.6	—	—
Cash from Financing Activities	175.1	227.8	-29.0	22.6	11.0	16.3	-16.5	-6.4	-34.8	168.7	63.1
Dividends Paid	12.6	8.2	8.1	8.9	7.5	7.6	7.7	7.7	7.7	—	—
Net Change in Cash	64.4	29.8	-28.7	65.8	-72.2	129.4	-27.7	-40.0	28.9	5.2	21.6

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	570.8	492.7	516.3	542.2	528.4	481.4	503.9	515.9	473.3	443.9
Gross Profit	—	—	—	—	—	—	—	515.9	473.3	443.9
Operating Income	76.6	47.8	34.8	80.5	85.3	61.1	63.0	101.7	68.7	48.5
Finance Income	5.1	32.2	4.7	5.9	4.9	4.0	11.9	2.8	5.3	4.9
Finance Costs	11.1	7.9	13.2	3.6	14.9	10.5	33.2	7.6	-1.6	6.7
Pretax Income	40.6	67.9	49.7	80.1	69.2	44.6	-28.5	57.5	54.9	31.8
Income Tax Expense	4.2	14.6	-19.7	17.4	7.9	10.1	4.0	-0.5	36.5	-6.8
Net Income	36.3	53.3	69.4	62.7	61.3	34.5	-32.5	58.0	18.4	25.0
Total Comprehensive Income	24.1	88.9	104.9	66.8	45.0	25.0	-45.1	73.0	-23.8	65.1

Breakdown ₩ tn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	3.48	3.41	3.23	3.10	2.89	2.76	2.72	2.65	2.55	2.47
Current Assets	1.11	1.08	1.03	1.13	1.03	0.96	0.95	0.90	0.89	0.87
Cash & Cash Equivalents	0.27	0.26	0.26	0.29	0.23	0.18	0.19	0.21	0.16	0.21
Inventories	0.47	0.46	0.44	0.46	0.45	0.41	0.39	0.37	0.38	0.37
Trade Receivables	0.31	0.28	0.27	0.27	0.26	0.27	0.27	0.24	0.26	0.21
Non-current Assets	2.36	2.33	2.20	1.97	1.86	1.79	1.77	1.75	1.66	1.60
Property, Plant & Equipment	1.25	1.20	1.15	1.13	1.04	0.99	0.96	0.90	0.85	0.77
Intangible Assets	0.40	0.40	0.38	0.38	0.37	0.36	0.36	0.34	0.33	0.31
Total Liabilities	1.60	1.55	1.46	1.47	1.33	1.24	1.22	1.11	1.08	0.97
Current Liabilities	1.11	0.90	0.77	0.78	0.71	0.68	0.72	0.61	0.66	0.73
Non-current Liabilities	0.49	0.66	0.70	0.68	0.62	0.56	0.50	0.50	0.41	0.24
Total Equity	1.88	1.85	1.77	1.63	1.56	1.52	1.50	1.54	1.47	1.49
Share Capital	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03	0.03
Retained Earnings	1.17	1.14	1.11	1.04	1.00	0.96	0.95	0.97	0.93	0.91

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	66.8	35.0	70.2	84.8	73.7	28.8	55.7	52.3	16.1	38.2
Cash from Investing Activities	-70.8	-100.5	-135.9	-105.3	-68.6	-57.7	-142.0	-71.5	-121.9	-30.1
Purchase of Property, Plant & Equipment	62.9	71.3	97.7	88.4	63.0	45.7	76.7	56.8	79.9	49.1
Cash from Financing Activities	14.1	65.8	32.4	72.4	56.9	13.4	63.0	66.5	63.2	35.2
Dividends Paid	11.6	1.0	0.0	1.2	—	—	0.0	0.4	—	—
Net Change in Cash	8.1	3.8	-33.0	54.8	58.3	-15.7	-19.4	47.0	-42.3	44.5

Consolidated (CFS), from DART. 11 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

003090 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	2,068.4	+6.8%	+6.8%	+8.8%	+7.6%
Operating income	261.8	-7.1%	+8.1%	+21.7%	+12.6%
Net income	227.9	+231.0%	+23.7%	+14.0%	+15.4%
EPS	₩3,920	+231.0%	+23.7%	+14.0%	+15.4%
Operating cash flow	257.6	+58.6%	+20.0%	+12.1%	+13.1%
Shareholders' equity	1,767.3	+17.6%	+11.4%	+9.7%	+7.9%

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

003090 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	12.7%	14.6%	10.8%	12.2%	12.1%	7.2%
Net margin	11.0%	3.6%	10.6%	7.1%	6.6%	8.7%
Return on equity	13.9%	4.7%	14.1%	9.9%	8.8%	11.1%
Return on assets	7.7%	2.7%	8.5%	5.9%	5.3%	6.8%
Operating cash flow / revenue	12.5%	8.4%	11.3%	8.8%	8.8%	10.7%
Capex / revenue	14.3%	13.6%	10.0%	4.0%	4.5%	2.3%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 003090

Symbol	Last Price
127120JS Link	₩33,600 +12.4%
475830Orum Therapeutics, Inc.	₩55,900 +2.6%
195940HK inno.N Corporation	₩42,050 +0.7%
086450Dong Kook Pharmaceutical Co., Ltd.	₩21,600 -0.9%
185750Chong Kun Dang Pharmaceutical Corp.	₩68,000 -0.3%
115180Qurient Co., Ltd.	₩23,050 +17.3%
476830Rznomics, Inc.	₩28,200 +6.8%
003850Boryung Corporation	₩9,040 +1.6%
950260Ingenia Therapeutics Inc.(reg.s)	₩15,580 -1.5%
085660Chabiotech Co., Ltd.	₩8,090 +2.1%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.